Manting Chiang
YOU?
Author Swipe
View article: Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM
Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM Open
Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypert…
View article: Pharmacokinetic Modeling of the Effect of Tariquidar on Ondansetron Disposition into the Central Nervous System
Pharmacokinetic Modeling of the Effect of Tariquidar on Ondansetron Disposition into the Central Nervous System Open
Purpose Serotonin (5-HT 3 ) receptor antagonists are promising agents for treatment of neuropathic pain. However, insufficient drug exposure at the central nervous system (CNS) might result in lack of efficacy. The goal of this study was t…
View article: Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants
Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants Open
View article: Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants
Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants Open
Two open‐label, Phase 1 studies assessed the effects of omeprazole (a weak to moderate cytochrome P450 [CYP] 2C19 inhibitor) and verapamil (a moderate CYP3A4 inhibitor) on the pharmacokinetics, safety, and tolerability of mavacamten. In th…
View article: Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21 Open
Physiologically based pharmacokinetic (PBPK) modeling has a number of applications, including assessing drug–drug interactions (DDIs) in polymorphic populations, and should be iteratively refined as science progresses. The Simcyp Simulator…
View article: Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System
Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System Open
View article: Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans
Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans Open
Aims Changes in serotonergic sensory modulation associated with overexpression of 5‐HT 3 receptors in the central nervous system (CNS) have been implicated in the pathophysiology of neuropathic pain after peripheral nerve damage. 5‐HT 3 re…
View article: Pharmacokinetic modeling of CNS disposition of 5-HT<sub>3</sub> receptor antagonist with quantitative assessment of the role of P-glycoprotein efflux
Pharmacokinetic modeling of CNS disposition of 5-HT<sub>3</sub> receptor antagonist with quantitative assessment of the role of P-glycoprotein efflux Open
Neuropathic pain is a chronic pain condition that affects 7-10% of the general population. The currently available treatments are often unable to provide sufficient pain relief for the patients or are prescribed at doses that produce toxic…
View article: Is rat a good model for assessment of particulate-based taste-masked formulations?
Is rat a good model for assessment of particulate-based taste-masked formulations? Open
View article: Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography‐ultraviolet method
Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography‐ultraviolet method Open
Ondansetron, a widely used antiemetic agent, is a P‐glycoprotein (P‐gp) substrate and therefore expression of P‐gp at the blood–brain barrier limits its distribution to the central nervous system (CNS), which was observed to be reversed by…
View article: Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system
Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system Open